Updated NCCN Clinical Practice Guidelines Provides a New Recommendation for Ropeginterferon alfa-2b-njft

On May 23, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have been updated to include BESREMi® (ropeginterferon alfa-2b-njft) as a preferred therapeutic option for the treatment of adults with both high and low-risk polycythemia vera, regardless of treatment history. 

For more information read the PharmaEssentia announcement.

Posted 6/8/2023